0001193125-20-166769.txt : 20200611 0001193125-20-166769.hdr.sgml : 20200611 20200611172111 ACCESSION NUMBER: 0001193125-20-166769 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200610 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20200611 DATE AS OF CHANGE: 20200611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Homology Medicines, Inc. CENTRAL INDEX KEY: 0001661998 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473468154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38433 FILM NUMBER: 20958012 BUSINESS ADDRESS: STREET 1: ONE PATRIOTS PARK CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-301-7277 MAIL ADDRESS: STREET 1: ONE PATRIOTS PARK CITY: BEDFORD STATE: MA ZIP: 01730 8-K 1 d943446d8k.htm 8-K 8-K
false 0001661998 0001661998 2020-06-10 2020-06-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2020

 

HOMOLOGY MEDICINES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

  

001-38433

  

47-3468154

(State or other jurisdiction of
incorporation or organization)

  

(Commission
File Number)

  

(I.R.S. Employer
Identification No.)

One Patriots Park
Bedford, MA

  

01730

(Address of principal executive offices)

  

(Zip Code)

(781) 301-7277

(Registrant’s telephone number, include area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock,

$0.0001 par value per share

  

FIXX

  

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 10, 2020, Homology Medicines, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 43,247,091 shares of common stock were present online or represented by proxy at the meeting, representing approximately 95.7% percent of the Company’s outstanding common stock as of the April 17, 2020 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2020.

Item 1 — Election of three Class II Directors to serve until the 2023 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

NOMINEE

 

Votes FOR

 

Votes WITHHELD

 

Broker Non-Votes

Steven Gillis, Ph.D.

 

36,671,773

 

2,011,744

 

4,563,574

Richard J. Gregory, Ph.D.

 

37,237,578

 

1,445,939

 

4,563,574

Kush M. Parmar, M.D, Ph.D.

 

36,912,102

 

1,771,415

 

4,563,574

Item 2 — Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2020.

Votes FOR

 

Votes AGAINST

 

Votes ABSTAINED

 

Broker Non-Votes

43,166,375

 

49,235

 

31,481

 

0

Based on the foregoing votes, Steven Gillis, Ph.D., Richard J. Gregory, Ph.D. and Kush M. Parmar, M.D, Ph.D. were elected as Class II Directors and Item 2 was approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

HOMOLOGY MEDICINES, INC.

  

                 

Date: June 11, 2020

 

 

By:

 

/s/ W. Bradford Smith

 

 

 

 

W. Bradford Smith

 

 

 

 

Chief Financial Officer and Treasurer

 

EX-101.SCH 2 fixx-20200610.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 fixx-20200610_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 fixx-20200610_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d943446d8k.htm fixx-20200610.xsd fixx-20200610_lab.xml fixx-20200610_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false ZIP 7 0001193125-20-166769-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-166769-xbrl.zip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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 d943446d8k_htm.xml IDEA: XBRL DOCUMENT 0001661998 2020-06-10 2020-06-10 false 0001661998 8-K 2020-06-10 HOMOLOGY MEDICINES, INC. DE 001-38433 47-3468154 One Patriots Park Bedford MA 01730 (781) 301-7277 false false false false Common Stock, $0.0001 par value per share FIXX NASDAQ true false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Jun. 10, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001661998
Document Type 8-K
Document Period End Date Jun. 10, 2020
Entity Registrant Name HOMOLOGY MEDICINES, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38433
Entity Tax Identification Number 47-3468154
Entity Address, Address Line One One Patriots Park
Entity Address, City or Town Bedford
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01730
City Area Code (781)
Local Phone Number 301-7277
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol FIXX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d943446d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d943446d8k.htm" ] }, "labelLink": { "local": [ "fixx-20200610_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "fixx-20200610_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "fixx-20200610.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fixx", "nsuri": "http://www.homologymedicines.com/20200610", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d943446d8k.htm", "contextRef": "duration_2020-06-10_to_2020-06-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d943446d8k.htm", "contextRef": "duration_2020-06-10_to_2020-06-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.homologymedicines.com//20200610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" }